FDA advisers say new Alzheimer’s drug lecanemab slows cognitive decline

Panel’s opinion could pave way for full regulatory approval next month for treatment of disease that affects 6.5m Americans

A panel that advises the Food and Drug Administration agreed that a new drug to treat Alzheimer’s disease was beneficial for slowing cognitive decline, paving the way for full regulatory approval next month.

Earlier this year, the drug, known as lecanemab, was granted partial, or accelerated, approval, but that restricted it to people who could pay $26,500 a year or were enrolled in a clinical trial. Under its current status, it is not available under the public health programs Medicare and Medicaid.